127 Result: Surgery
Jazz Pharma, Zymeworks: Promising Data on Zanidatamab in HER2-Amplified BTC; Positive View on Trade Desk, Kura Sushi and Surgery Partners
June 03rd, 2023
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Zymeworks Inc. (Nasdaq: ZYME) shared encouraging results from the pivotal Phase 2b HERIZON-BTC-01 trial, which assessed the efficacy of Zanidatamab, an investigational bispecific antibody developed on Zymew. Read more
Lucintel Forecasts Medical Camera Market to grow at a CAGR of 9% during 2019 to 2024
December 08th, 2021
Dallas, TX / CRWE PRESS RELEASE / Dec. 9, 2021 - According to the recent study the Medical Camera Market is projected to grow at a CAGR of 9% during 2019 to 2024. Growth in this market is primarily driven by increasing demand for bio-ethanol and. Read more
Shire's First Prescription Eye Drop, Xiidra(TM) (lifitegrast ophthalmic solution) 5% Is Now Available in the U.S.
August 29th, 2016
Xiidra is the onlyprescription eye drop approved by the U.S. FDA for the treatment of both signs and symptoms of dry eye disease Resources are available to support patients seeking information regarding coverage and savings offers Xiidra is t. Read more
Nymox's New Phase 3 Long-Term U.S. Results For Prostate Enlargement Drug Fexapotide Show
August 29th, 2016
1. Dramatic Decrease in Prostate Cancer and 2. Major Reduction in Need For BPH Prostate Surgery HASBROUCK HEIGHTS, N.J. / CRWE PRESS RELEASE / August 29, 2016 - Nymox Pharmaceutical Corporation (NASDAQ:NYMX) lead drug fexapotide which has been . Read more
Puma Biotechnology Announces European Medicines Agency Validation of Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in Europe
August 22nd, 2016
LOS ANGELES, Calif. / CRWE PRESS RELEASE / August 22, 2016 - Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that the Marketing Authorization Application (MAA) for neratinib has been validated by the European Medicines A. Read more
Medtronic Completes $20 Million Second Tranche Investment In Mazor Robotics
August 15th, 2016
CAESAREA, Israel / CRWE PRESS RELEASE / August 15, 2016 – Mazor Robotics Ltd. (TASE: MZOR; NASDAQGM: MZOR), a pioneer and a leader in the field of surgical guidance systems, today announced the completion of the second tranche of the equity inv. Read more
EyeGate Announces Positive Top-line Data from Phase 1b/2a Clinical Trial of EGP-437 for Treatment of Post-Operative Inflammation and Pain in Cataract Surgery Patients
August 01st, 2016
WALTHAM, Mass. / CRWE PRESS RELEASE / Aug. 01, 2016 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing produ. Read more
ONIVYDE(R) Receives Positive CHMP Opinion for Treatment of Patients with Metastatic Adenocarcinoma of the Pancreas who have Progressed Following Gemcitabine based Therapy
July 25th, 2016
The positive opinion is based on a pivotal Phase 3 study showing that ONIVYDE combined with chemotherapy significantly increased overall survival (OS) in patients with metastatic pancreatic cancer after previous gemcitabine based therapy Zug, Swit. Read more
Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data from Phase III Trial of PB272 (Neratinib) in Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET Trial)
July 21st, 2016
LOS ANGELES, Calif. / CRWE PRESS RELEASE / July 21, 2016 - Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced updated results from the Phase III clinical trial of Puma's investigational drug PB272 (neratinib) for t. Read more
Puma Biotechnology Submits New Drug Application for PB272 (Neratinib) to U.S. FDA for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
July 21st, 2016
LOS ANGELES, Calif. / CRWE PRESS RELEASE / July 21, 2016 - Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead product candida. Read more
VBI Vaccines Announces Medulloblastoma Immunotherapy Program
June 16th, 2016
Cambridge, Massachusetts / CRWE PRESS RELEASE / June 16, 2016 - VBI Vaccines Inc. (Nasdaq: VBIV and TSX: VBV) (“VBI”) today announced that it is developing a novel therapeutic vaccine candidate for medulloblastoma. The Meghan Rose Bradley. Read more
Catabasis Pharmaceuticals Presents Positive Pre-Clinical Data at Digestive Disease Week 2016; Data Support CAT-2054, a Phase 2 Asset, as a Potential Treatment for Nonalcoholic Steatohepatitis (NASH)
May 22nd, 2016
CAMBRIDGE, MA / CRWE PRESS RELEASE / May 21, 2016 - Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced positive pre-clinical data supporting CAT-2054 as a potential treatment for nonalcoholic st. Read more
NOVADAQ Announces Fourth Quarter 2015 Preliminary Unaudited Revenues and Issues 2016 Revenue Guidance
January 11th, 2016
Toronto, Ontario / CRWEPRESSRELEASE / January 11, 2016 - Novadaq Technologies Inc. (“NOVADAQ” or the “Company”) (NASDAQ:NVDQ; TSX:NDQ), the leading developer and provider of clinically relevant fluorescence imaging solutions f. Read more
CEL-SCI Corporation Summarizes Significant Accomplishments in 2015 and Positive Momentum for 2016
January 08th, 2016
Vienna, VA / CRWEPRESSRELEASE / January 8, 2016 -- The following letter is being released by CEL-SCI Corporation (NYSE MKT: CVM) to its shareholders: Dear Fellow Shareholders: As CEL-SCI shareholders most of you have been following the progress. Read more
FDA approves Bridion to reverse effects of neuromuscular blocking drugs used during surgery
December 15th, 2015
First drug approved in new class of medications December 15, 2015 - The U.S. Food and Drug Administration today approved Bridion (sugammadex) injection to reverse the effects of neuromuscular blockade induced by rocuronium bromide and vecuronium b. Read more
Want To Find Some News?
News By Industries
Recent Post
-
June 03rd, 2023June 02nd, 2023June 02nd, 2023